Optimizing Virus Bank Manufacturing

The production of viral vectors for the manufacturing of gene therapies and vaccines depends on the development and utilization of high-quality master and working virus seed stocks (MVSS and WVSS). Developing these seed stocks can be challenging, particularly for innovators with limited experience in their production. In the following, two case studies illustrate how the highly skilled team at MilliporeSigma's GMP facility in Glasgow, Scotland, aided clients in overcoming obstacles during virus bank manufacturing.

The first case highlights the technical transfer step, which involves a non-GMP assessment of the client's parameters to ensure the process is robust before transitioning to GMP. The second case explores the adjustments made to a process during the preparation of materials and documentation for the GMP campaign.